Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NMT2 | O60551 | 1/20 | 0.58 |
| ▸ | NMT1 | P30419 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3906503 | 0.90 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL29860485 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL27659536 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL31442541 | 0.87 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL10256511 | 0.87 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL14238204 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL27276256 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL27327783 | 0.86 | KDM4E (0.57) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL11075264 | 0.86 | KDM4E (0.61) | SMN1; SMN2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL28126276 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117917400-A | 2-Methyl-4-quinolinone compound, and pharmaceutical composition and application thereof | 暨南大学 | 2024-04-23 | — | — | CN | disclosed |
| US-8598159-B2 | Therapeutic pyrazoloquinoline derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-12-03 | — | — | US | disclosed |
| EP-2164328-B1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | DART NEUROSCIENCE CAYMAN LTD (KY) | 2013-08-07 | — | — | EP | disclosed |
| US-8343957-B2 | Therapeutic pyrazoloquinoline urea derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-01-01 | — | — | US | disclosed |
| EP-2166852-B1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7863266-B2 | Therapeutic pyrazoloquinoline urea derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| CN-101742908-A | therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS INC | 2010-06-16 | — | — | CN | disclosed |
| EP-2166852-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | Helicon Therapeutics, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| CN-101686682-A | therapeutic pyrazoloquinoline urea derivatives | HELICON THERAPEUTICS INC | 2010-03-31 | — | — | CN | disclosed |
| EP-2164328-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | Helicon Therapeutics, Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008154438-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154442-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306048-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-4450166-A | N-(4,5-Dihydro-thiazol-2-yl)-3-quinoline-carboxamides having anxiolytic activity | ROUSSEL UCLAF (FR) | 1984-05-22 | — | — | US | disclosed |
| US-4450167-A | TRANQUILIZERS; PSYCHOLOGICAL DISORDERS | ROUSSEL UCLAF (FR) | 1984-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | SMN1; SMN2 2752/4885LMNA 3212/4885MEN1 3172/4885 |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | SMN1; SMN2 2752/4885LMNA 3212/4885MEN1 3172/4885 |
| US-20080306048-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | GABRB1, GABRA5, GABRB2 | SMN1; SMN2 3284/4885LMNA 4010/4885MEN1 4121/4885 |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | GABRB1, GABRA5, GABRB2 | SMN1; SMN2 3284/4885LMNA 4010/4885MEN1 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.